REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,189,811 | +0.0% | 70,516 | -10.8% | 0.00% | -33.3% |
| Q1 2023 | $7,186,590 | +266.4% | 79,043 | +53.1% | 0.00% | +200.0% |
| Q4 2022 | $1,961,234 | -15.5% | 51,625 | -32.4% | 0.00% | 0.0% |
| Q2 2022 | $2,320,000 | -57.7% | 76,351 | -54.4% | 0.00% | -50.0% |
| Q1 2022 | $5,482,000 | +141.1% | 167,329 | +94.1% | 0.00% | – |
| Q4 2021 | $2,274,000 | -81.2% | 86,222 | -28.3% | 0.00% | -100.0% |
| Q3 2021 | $12,093,000 | -8.7% | 120,183 | +28.5% | 0.00% | -20.0% |
| Q2 2021 | $13,241,000 | +21.2% | 93,561 | -14.6% | 0.01% | -16.7% |
| Q1 2021 | $10,925,000 | +42.6% | 109,574 | +76.8% | 0.01% | +50.0% |
| Q4 2020 | $7,661,000 | -43.2% | 61,974 | -55.2% | 0.00% | -50.0% |
| Q3 2020 | $13,491,000 | -3.3% | 138,489 | +54.8% | 0.01% | -20.0% |
| Q2 2020 | $13,955,000 | +15.0% | 89,446 | +6.4% | 0.01% | -16.7% |
| Q1 2020 | $12,131,000 | +847.0% | 84,054 | +1241.2% | 0.01% | +500.0% |
| Q4 2019 | $1,281,000 | +442.8% | 6,267 | +127.2% | 0.00% | – |
| Q1 2019 | $236,000 | – | 2,758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $295,368,026 | 59.26% |
| Ally Bridge Group (NY) LLC | 105,558 | $10,762,694 | 13.04% |
| First Light Asset Management, LLC | 1,432,208 | $146,027,928 | 11.44% |
| Boxer Capital, LLC | 1,430,004 | $145,803 | 6.76% |
| MPM BioImpact LLC | 234,478 | $23,907,377 | 4.81% |
| Tri Locum Partners LP | 96,274 | $9,816,097 | 3.65% |
| Altium Capital Management LP | 41,485 | $4,229,811 | 3.20% |
| Ghost Tree Capital, LLC | 85,000 | $8,666,600 | 2.86% |
| KRS Capital Management, LLC | 27,941 | $2,848,864 | 2.85% |
| Sofinnova Investments, Inc. | 322,471 | $32,879,143 | 2.15% |